A Peptide Targeted Contrast Agent Specific to Fibrin-Fibronectin Complexes for Cancer Molecular Imaging with MRI
Year: 2008
Type: article
Abstract: A peptide targeted contrast agent, CLT1-(Gd-DTPA), was synthesized for molecular imaging of fibronectin-fibrin complexes in tumor tissue with magnetic resonance imaging (MRI). The T(1) and T(2) relaxivities of CLT1-(Gd-DTPA) were 4.22 and 4.45 mM(-1) s(-1) at 3 T, respectively. The targeted contrast agent specifically bound to tumor tissue and resulted in significant tumor contrast enhancement at a dose of 0.1 mmol Gd/kg for at least 60 min in mice bearing HT-29 human colon carcinoma xenografts as shown in dynamic MR images. In contrast, a control nontargeted contrast agent, Gd(DTPA-BMA), was cleared rapidly with little tumor enhancement 60 min postinjection. Tumor enhancement with CLT1-(Gd-DTPA) was significantly reduced after coinjection with a 3-fold excess of free CLT1 peptide. The preliminary study has shown that CLT1-(Gd-DTPA) can specifically bind to the fibrin-fibronectin complexes in tumor tissues, resulting in significant tumor enhancement. The targeted contrast agent has a potential for cancer molecular imaging with MRI.
Source: Bioconjugate Chemistry
DOI: 10.1021/bc800211r
Authors: Furong Ye, Eun-Kee Jeong, Zhanjun Jia, Tianxin Yang, Denis Parker, Zheng-Rong Lu
Institutions: University of Utah, VA Salt Lake City Healthcare System
Language: English
Subfield: Materials Chemistry
Field: Materials Science
Domain: Physical Sciences
Open Access status: hybrid
Estimated APC paid: $4,500
Awards: Biodegradable Macromolecular Blood Pool Contrast Agents, Polymer chelate conjugates for diagnostic cancer imaging, Biodegradable Macromolecular MRI Contrast Agents, G5520316217, Biodegradable Macromolecular MRI Contrast Agents, Multifunctional Carriers for Systemic siRNA Delivery, Minimally-Invasive Image-Guided Therapy for Cancer Treatment
OpenAlex ID: W1982999028
